Complexed prostate-specific antigen improvement in detecting prostate cancer

K Okihara; R J Babaian

doi:10.1007/s11934-001-0088-7

Complexed prostate-specific antigen improvement in detecting prostate cancer

Curr Urol Rep. 2001 Jun;2(3):253-8. doi: 10.1007/s11934-001-0088-7.

Authors

K Okihara¹, R J Babaian

Affiliation

¹ Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA. [email protected]

PMID: 12084274
DOI: 10.1007/s11934-001-0088-7

Abstract

This article presents the current reports of complexed prostate-specific antigen (PSA) aimed for the enhancement of prostate cancer detection. Further studies are needed to ascertain the variability of complexed PSA. Comparisons of percent free PSA, potential additive value of alpha(1)-antichymotripsin-bound PSA (PSA-ACT) and Bayer complexed PSA (cPSA) remains controversial in men with intermediate elevated total PSA concentration. Volume-referenced complexed PSA (PSA-ACT and cPSA) can enhance prostate cancer detection. Preliminary results show that PSA-alpha(2)-macrobloblin (PSA-a(2)M) and PSA-alpha(1)-protease inhibitor (PSA-API) are promising assays for improving cancer detection.

Publication types

Review

MeSH terms

Humans
Male
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*
Prostatic Neoplasms / diagnosis*
Sensitivity and Specificity

Substances

Prostate-Specific Antigen